Download PDF
Semin Thromb Hemost 2006; 32(3): 267-275
DOI: 10.1055/s-2006-939438
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Diagnosis and Therapy of Polycythemia Vera

Eva Lengfelder1 , Kirsten Merx1 , Rüdiger Hehlmann1
  • 1III. Medizinische Klinik Mannheim, University of Heidelberg Mannheim, Germany
Further Information

Publication History

Publication Date:
02 May 2006 (online)

    Permissions and Reprints

ABSTRACT

Polycythemia vera (PV) is a hematopoietic stem cell disorder characterized by a predominant proliferation of the erythroid cell line. The diagnosis is commonly based on the WHO criteria. The acquired V617F mutation in the tyrosine kinase gene JAK2 represents a new molecular marker proving clonality in PV and other chronic myeloproliferative disorders. Phlebotomy is still the treatment of choice to reduce the red cell mass. Low-dose acetylsalicylic acid is successful in the primary prophylaxis of vascular complications. However, the majority of patients require myelosuppressive therapy during the course of their disease due to progressive myeloproliferation. Hydroxyurea still plays a role in patients of all age groups. Interferon α represents an alternative, particularly for younger patients. Apart from sporadic cases of bone marrow transplantation, there is no known curative treatment in PV. To date, the diagnosis of PV was based mainly on clinical criteria. The identification of the JAK2 mutation enables new approaches to the diagnosis, classification, and treatment of PV and of the other myeloproliferative disorders.

KEYWORDS

Polycythemia vera - diagnosis - therapy - leukemia - myelofibrosis - thrombosis

REFERENCES

  • 1 Dameshek W. Some speculations on the myeloproliferative syndromes.  Blood. 1951;  6 372-375
    PubMedGoogle Scholar
  • 2 Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Polycythemia vera. In: Jaffe E, Harris N, Stein H, Vardiman J Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press 2001: 32-34
    Google Scholar
  • 3 Thiele J, Kvasnicka H M, Fischer R, Diehl V. Histochemistry and morphometry on bone marrow specimens in chronic myeloproliferative disorders - aids to diagnosis and classification.  Ann Hematol. 1999;  78 495-506
    CrossrefPubMedGoogle Scholar
  • 4 Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.  N Engl J Med. 1998;  338 564-571
    CrossrefPubMedGoogle Scholar
  • 5 Moliterno A, Hankins D, Spivak J. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.  N Engl J Med. 1998;  338 572-580
    CrossrefPubMedGoogle Scholar
  • 6 Klippel S, Strunck S, Temerinac S et al.. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.  Blood. 2003;  102 3569-3574
    CrossrefPubMedGoogle Scholar
  • 7 Teofili L, Martini M, Luongo M et al.. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.  J Clin Oncol. 2002;  20 4249-4254
    CrossrefPubMedGoogle Scholar
  • 8 Palmqvist L, Goerttler P, Wasslavik C et al.. Comparison of methods for polycythemia rubra vera-1 mRNA quantification in whole-blood leukocytes and purified granulocytes.  Clin Chem. 2004;  50 644-647
    PubMedGoogle Scholar
  • 9 Emig M, Ernst T, Schenk T et al.. Relationship of PRV1 expression and JAK2 V617F mutations in chronic myeloproliferative disorders.  Onkologie. 2005;  28(suppl 3) 136 (abst 409)
    PubMedGoogle Scholar
  • 10 Kralovics R, Passamonti F, Buser A et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352 1779-1790
    CrossrefPubMedGoogle Scholar
  • 11 Baxter E, Scott L, Campbell P et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet. 2005;  365 1054-1061
    CrossrefPubMedGoogle Scholar
  • 12 James C, Ugo V, Couédic J et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.  Nature. 2005;  434 1144-1148
    CrossrefPubMedGoogle Scholar
  • 13 Levine R, Wadleigh M, Cools J et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.  Cancer Cell. 2005;  7 387-397
    CrossrefPubMedGoogle Scholar
  • 14 Jones A, Kreil S, Zoi K et al.. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.  Blood. 2005;  106 2162-2168
    CrossrefPubMedGoogle Scholar
  • 15 Gruppo Italiano Studio Polycythemia vera. The natural history of 1213 patients followed for 20 years.  Ann Intern Med. 1995;  123 656-664
    PubMedGoogle Scholar
  • 16 Najean Y, Dresch C, Rain J D. The very-long-term course of polycythemia: a complement to the previously published data of the polycythemia vera study group.  Br J Haematol. 1994;  86 233-235
    PubMedGoogle Scholar
  • 17 Rozman C, Giralt M, Feliu E, Rubio D, Cortés M T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.  Cancer. 1991;  67 2658-2663
    PubMedGoogle Scholar
  • 18 Passamonti F, Malabarba L, Orlandi E et al.. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.  Haematologica. 2003;  88 13-18
    PubMedGoogle Scholar
  • 19 Najean Y, Mugnier P, Dresch C, Rain J. Polycythemia vera in young people. An analysis of 58 cases diagnosed before 40 years.  Br J Haematol. 1987;  67 285-291
    PubMedGoogle Scholar
  • 20 Berk P D, Goldberg J D, Silverstein M N et al.. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.  N Engl J Med. 1981;  304 441-447
    CrossrefPubMedGoogle Scholar
  • 21 Berk P D, Goldberg J D, Donovan P D, Fruchtman S M, Berlin N I, Wasserman L R. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols.  Semin Hematol. 1986;  23 132-143
    PubMedGoogle Scholar
  • 22 Messinezy M, Pearson T C. Incidence of myelofibrosis following treatment of primary polycythaemia by venesection.  Br J Haematol. 1995;  89 228-229
    PubMedGoogle Scholar
  • 23 Haanen C, Mathé G, Hayat M. Treatment of polycythemia vera by radiophosphorus or busulfan: a randomized trial.  Br J Cancer. 1981;  44 75-80
    CrossrefPubMedGoogle Scholar
  • 24 Najean Y, Rain J D. for the French Polycythemia Study Group . Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age.  Blood. 1997;  89 2319-2327
    PubMedGoogle Scholar
  • 25 Fruchtman S M, Mack K, Kaplan M E, Peterson P, Berk P D, Wasserman L R. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera.  Semin Hematol. 1997;  34 17-23
    PubMedGoogle Scholar
  • 26 Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea.  Semin Hematol. 1997;  34 24-28
    PubMedGoogle Scholar
  • 27 Najean Y, Rain J D. for the French Polycythemia Study Group . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.  Blood. 1997;  90 3370-3377
    PubMedGoogle Scholar
  • 28 Finazzi G, Ruggeri M, Rodheghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow up of a randomized trial.  Br J Haematol. 2000;  110 577-583
    CrossrefPubMedGoogle Scholar
  • 29 Finazzi G, Caruso V, Marchioli R et al.. ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.  Blood. 2005;  105 2664-2670
    CrossrefPubMedGoogle Scholar
  • 30 Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.  J Clin Oncol. 1984;  2 558-561
    PubMedGoogle Scholar
  • 31 Petti M C, Spadea A, Avvisati G et al.. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).  Leukemia. 1998;  12 869-874
    CrossrefPubMedGoogle Scholar
  • 32 Passamonti F, Brusalimo E, Lazzarino M et al.. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.  Haematologica. 2000;  85 1011-1018
    PubMedGoogle Scholar
  • 33 Kiladjian J J, Gardin C, Renoux M, Bruno F, Bernard J F. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.  Hematol J. 2003;  4 198-207
    CrossrefPubMedGoogle Scholar
  • 34 Lengfelder E, Berger U, Hehlmann R. Interferon α in the treatment of polycythemia vera.  Ann Hematol. 2000;  79 103-109
    CrossrefPubMedGoogle Scholar
  • 35 Gilbert H S. Long term treatment of myeloproliferative disease with interferon-α-2b.  Cancer. 1998;  83 1205-1213
    CrossrefPubMedGoogle Scholar
  • 36 Merx K, Fabarius A, Pahl H et al.. Pegylated interferon alpha (PegIntron) in patients with polycythemia vera. A prospective multicenter phase II Study.  Onkologie. 2004;  27(suppl 3) 74 (abst O 363)
    PubMedGoogle Scholar
  • 37 Anagrelide study group . Anagrelide, a therapy for thrombocythemic states: experience in 577 patients.  Am J Med. 1992;  92 69-76
    CrossrefPubMedGoogle Scholar
  • 38 Fruchtman S M. Treatment paradigms in the management of myeloproliferative disorders.  Semin Hematol. 2004;  42(suppl 3) 18-22
    PubMedGoogle Scholar
  • 39 Storen E, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.  Blood. 2001;  97 863-866
    CrossrefPubMedGoogle Scholar
  • 40 Harrison C N, Campbell P J, Buck G et al.. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.  N Engl J Med. 2005;  353 33-45
    CrossrefPubMedGoogle Scholar
  • 41 Silver R T. Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera.  Leukemia. 2003;  17 1186-1187
    CrossrefPubMedGoogle Scholar
  • 42 Silver R T, Fruchtman S M, Feldman E J, Spivak J L, Salvado A J. Imatinib mesylate (GLEEVEC) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial.  Blood. 2004;  104 (abst 656)
    PubMedGoogle Scholar
  • 43 Hasselbalch H C, Pedersen M, Bostrom H. Imatinib mesylate therapy reduces phlebotomy requirements in polycythemia vera.  Blood. 2003;  102 (abst 5087)
    PubMedGoogle Scholar
  • 44 Borthakur G, Kantarjian H, Vesrtovsek S et al.. Imatinib mesylate therapy for patients with polycythemia vera.  Blood. 2004;  104 (abst 1527)
    PubMedGoogle Scholar
  • 45 Hasselbalch H C, Larsen T S, Henriksen A S et al.. Imatinib mesylate in polycythemia vera. A Heterogeneous Response pattern but a consistent reduction in phlebotomy requirements.  Blood. 2004;  104 (abst 4747)
    PubMedGoogle Scholar
  • 46 Kuriakose P, Shurafa M S. A phase II trial of imatinib mesylate (Gleevec) in myeloproliferative disorders.  Blood. 2004;  104 (abst 4765)
    PubMedGoogle Scholar
  • 47 Jones C M, Dickinson T M. Polycythemia vera responds to imatinib mesylate.  Am J Med Sci. 2003;  325 149-152
    PubMedGoogle Scholar
  • 48 Merx K, Maywald O, Fabarius A et al.. Imatinib (Glivec®) therapy in patients with polycythemia vera. Interim analyses of an open label phase II trial.  Onkologie. 2005;  27(suppl 3) 80 (abst 235)
    PubMedGoogle Scholar
  • 49 Tartaglia A, Goldberg J D, Berk P D, Wasserman L R. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.  Semin Hematol. 1986;  23 172-176
    PubMedGoogle Scholar
  • 50 Gruppo Italiano Studio Polycythemia vera. Low dose aspirin in polycythemia vera: a pilot study.  Br J Haematol. 1997;  97 453-456
    CrossrefPubMedGoogle Scholar
  • 51 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350 114-124
    CrossrefPubMedGoogle Scholar

Eva LengfelderM.D. 

Priv. Dozent, III. Medizinische Universitätsklinik

Wiesbadenerstrasse 7-11, 68305 Mannheim, Germany

Email: eva.lengfelder@med3.ma.uni-heidelberg.de

      >